- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00441948
Enhanced Safety Laser Hair Removal System
Peterio™ - an Add-on Device for Enhanced Safety of Aesthetic Laser Treatments.
Study Overview
Detailed Description
Lasers are a well-established, popular modality for removal of unwanted hair. The existing lasers are based on a wavelength that is specifically absorbed by the pigment melanin found in the hair follicle, where the energy is converted to heat resulting in a thermal injury.
However, lasers for hair removal are not without limitations. A laser based long-term hair removal treatment is based on thermal destruction of the hair shaft and follicle using wavelengths that are specifically absorbed by the pigment melanin found in the hair follicle. The heating of hair follicle is done through heat dissipation from the hair shaft. One of the significant limitations of this approach is the fact that the epidermis through which the light energy must penetrate is rich in melanin and therefore absorbs a major portion of the energy, resulting in inadequate heating of the hair follicles. The purpose of the study is an evaluation safety and efficacy of a new laser based device.
Study Type
Enrollment
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Leon Gilad, MD
- Phone Number: 972-26235262
- Email: leong@cc.huji.ac.il
Study Locations
-
-
-
Jerusalem, Israel, 91120
- Hadassah Medical Center, Dermatology
-
Principal Investigator:
- Leon Gilad, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age between 18 and 75 years old
- Fitzpatrick skin types I to VI
Exclusion Criteria:
- Age below 18 or above 75 year old
- Use of photosensitive medications
- Photosensitive diseases
- Active infection of any type and active infection or or a history of Herpes Simplex in the treated site
- Exposure to sun or artificial tanning during the last 3-4 weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Hair reduction as counted 1-3 months after each treatment session, depending on the treated area.
|
Long term clearance will be calculated as the ratio between the value of the baseline hair count taken immediately before the first treatment, and the value obtained at the 3-6 month post treatment hair count.
|
Secondary Outcome Measures
Outcome Measure |
---|
Measuring treatment discomfort as graded by the patients.
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Leon Gilad, MD, Hadassah Medical Organization
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Peterio-05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hirsutism
-
Iran University of Medical SciencesFiruzgar hospital affiliated to Iran University of Medical SciencesCompletedIdiopathic Hirsutism
-
Alexander ShayestehRecruitingHypertrichosis | Hirsutism - HypertrichosisSweden
-
Istanbul Medeniyet UniversityUnknown
-
Bispebjerg HospitalCompleted
-
Follicum ABCompletedAlopecia | Hirsutism | HypertrichosisGermany
-
Medical Life Care Planners, LLCNot yet recruitingHair Diseases | Hirsutism
-
NHS Greater Glasgow and ClydeUnknown
-
BayerCompletedProstate Cancer | Signs of Androgenisation in Women, e.g. Hirsutism, Androgenetic Alopecia, Acne and Seborrhea | Hypersexuality in Men | Sexual Deviations in MenSpain, Germany, Netherlands, Poland, France
Clinical Trials on Peterio
-
Scilex Ltd.UnknownHirsutism | Rhytides | Hypertrichosis | TelangiectasesIsrael